163 results on '"D’alteroche, L"'
Search Results
2. Original Study: Transjugular Intrahepatic Portosystemic Shunt as a Bridge to Abdominal Surgery in Cirrhotic Patients
- Author
-
Tabchouri, N., Barbier, L., Menahem, B., Perarnau, J.-M., Muscari, F., Fares, N., D’Alteroche, L., Valette, P.-J., Dumortier, J., Alves, A., Lubrano, J., Bureau, C., and Salamé, Ephrem
- Published
- 2019
- Full Text
- View/download PDF
3. Short- and long-term evolution of the endoluminal diameter of underdilated stents in transjugular intrahepatic portosystemic shunt
- Author
-
Borghol, S., Perarnau, J.M., Pucheux, J., D’Alteroche, L., Ayoub, J., and Trillaud, H.
- Published
- 2016
- Full Text
- View/download PDF
4. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E
- Author
-
Perrin, H. Blasco, Cintas, P., Abravanel, F., Gerolami, R., d'Alteroche, L., Raynal, J.-N., Alric, L., Dupuis, E., Prudhomme, L., Vaucher, E., Couzigou, P., Liversain, J.-M., Bureau, C., Vinel, J.-P., Kamar, N., Izopet, J., and Peron, J.-M.
- Subjects
Hepatitis E -- Development and progression -- Care and treatment -- Health aspects ,Infection -- Development and progression -- Care and treatment -- Health aspects ,Miller Fisher syndrome -- Development and progression -- Care and treatment -- Health aspects ,Nervous system diseases -- Development and progression -- Care and treatment -- Health aspects ,Health ,American Medical Association - Abstract
Hepatitis E virus (HEV) infection is an emerging autochthonous disease in industrialized countries (1). Locally acquired (autochthonous) HEV 3 or HEV 4 infections are believed to be a porcine zoonosis. [...]
- Published
- 2015
- Full Text
- View/download PDF
5. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
- Author
-
Pageaux, G. (Georges-Philippe), Nzinga, C. (Clovis Lusivika), Ganne, N. (Nathalie), Samuel, D. (Didier), Dorival, C. (Céline), Zoulim, F. (Fabien), Cagnot, C. (Carole), Decaens, T. (Thomas), Thabut, D. (Dominique), Asselah, T. (Tarik), Mathurin, P. (Philippe), Habersetzer, F. (Francois), Bronowicki, J. (Jean-Pierre), Guyader, D. (Dominique), Rosa, I. (Isabelle), Leroy, V. (Vincent), Chazouilleres, O. (Olivier), de Ledinghen, V. (Victor), Bourliere, M. (Marc), Causse, X. (Xavier), Cales, P. (Paul), Metivier, S. (Sophie), Loustaud-Ratti, V. (Véronique), Riachi, G. (Ghassan), Alric, L. (Laurent), Gelu-Simeon, M. (Moana), Minello, A. (Anne), Gournay, J. (Jérôme), Geist, C. (Claire), Tran, A. (Albert), Abergel, A. (Armand), Portal, I. (Isabelle), d'Alteroche, L. (Louis), Raffi, F. (François), Fontaine, H. (Hélène), Carrat, F. (Fabrice), Pol, S. (Stanislas), Baumert, Thomas F., Doffoel, M. (Michel), Mutter, C. (Catherine), Simo-Noumbissie, P. (Pauline), Razi, E. (Esma), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathogénèse et Traitement des Maladies du Foie, Hôpital Paul Brousse-Université Paris-Saclay, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Physiopathologie des Maladies Inflammatoires de l'Intestin, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Pontchaillou [Rennes], Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHI Créteil, Biomécanique cellulaire et respiratoire (BCR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Joseph [Marseille], Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Université d'Angers (UA), CHU Toulouse [Toulouse], Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), French ANRS CO22 Hepather Cohort: Delphine Bonnet, Virginie Payssan-Sicart, Chloe Pomes, François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig-Lavie, Marianne Maynard, Eric Billaud, David Boutoille, Morane Cavellec, Caroline Chevalier, Isabelle Hubert, Pierre Goepfert, Adrien Lannes, Françoise Lunel, Jérôme Boursier, Nathalie Boyer, Nathalie Giuily, Corinne Castelnau, Giovanna Scoazec, Aziza Chibah, Sylvie Keser, Karim Bonardi, Anaïs Vallet-Pichard, Philippe Sogni, Juliette Foucher, Jean-Baptiste Hiriart, Amandine Legendre, Faiza Chermak, Marie Irlès-Depé, Si Nafa Si Ahmed, Christelle Ansaldi, Nisserine Ben Amara, Valérie Oules, Jacqueline Dunette, Rodolphe Anty, Eve Gelsi, Régine Truchi, Elena Luckina, Nadia Messaoudi, Joseph Moussali, Barbara De Dieuleveult, Héloïse Goin, Damien Labarrière, Pascal Potier, Si Nafa Si Ahmed, Véronique Grando-Lemaire, Pierre Nahon, Séverine Brulé, Rym Monard, Caroline Jezequel, Audrey Brener, Anne Laligant, Aline Rabot, Isabelle Renard, Thomas F Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo-Noumbissie, Esma Razi, Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani-Nani, Marie-Albertine Bernard, Georges-Philippe Pageaux, Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Marie Pierre Ripault, Christophe Bureau, Sarah Launay, Jean Marie Peron, Marie Angèle Robic, Léa Tarallo, Marine Faure, Bruno Froissart, Marie-Noelle Hilleret, Jean-Pierre Zarski, Odile Goria, Victorien Grard, Hélène Montialoux, Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault, Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty, Teresa Antonini, Audrey Coilly, Jean-Charles Duclos Vallée, Mariagrazia Tateo, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti, Abdenour Babouri, Virginie Filipe, Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah, Paul Carrier, Maryline Debette-Gratien, Jérémie Jacques, Guillaume Lassailly, Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet, Marianne Latournerie, Marc Bardou, Thomas Mouillot, Yannick Bacq, Didier Barbereau, Charlotte Nicolas, Caroline Chevalier, Isabelle Archambeaud, Sarah Habes, Nisserine Ben Amara, Danièle Botta-Fridlund, Eric Saillard, Marie-Josée Lafrance, Carole Cagnot, Alpha Diallo, Lena Wadouachi, Ventzi Petrov-Sanchez, Douae Ammour, Loubna Ayour, Jaouad Benhida, Fabrice Carrat, Frederic Chau, Céline Dorival, Audrey Gilibert, Isabelle Goderel, Warda Hadi, Clovis Luzivika Nzinga, Grégory Pannetier, François Pinot, Odile Stahl, François Téloulé, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Jonchère, Laurent
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Survival ,Hepatocellular carcinoma ,[SDV]Life Sciences [q-bio] ,Decompensated cirrhosis ,Infectious and parasitic diseases ,RC109-216 ,Hepacivirus ,Sciences du Vivant [q-bio]/Médecine humaine et pathologie ,complications ,drug therapy ,Gastroenterology ,Antiviral Agents ,Virological response ,Internal medicine ,Medicine ,Humans ,In patient ,business.industry ,Hepatitis C virus ,Research ,Liver Neoplasms ,Hepatitis C ,[SDV] Life Sciences [q-bio] ,Sustained virological response ,Infectious Diseases ,Direst-acting antiviral agents ,therapeutic use ,business ,After treatment - Abstract
Background In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the French ANRS CO22 HEPATHER cohort. Methods We identified HCV patients who had experienced an episode of decompensated cirrhosis. Study outcomes were all-cause mortality, liver-related or non-liver-related deaths, hepatocellular carcinoma, liver transplantation. Secondary study outcomes were sustained virological response and its clinical benefits. Results 559 patients met the identification criteria, of which 483 received direct antiviral agents and 76 remained untreated after inclusion in the cohort. The median follow-up time was 39.7 (IQR: 22.7–51) months. After adjustment for multivariate analysis, exposure to direct antiviral agents was associated with a decrease in all-cause mortality (HR 0.45, 95% CI 0.24–0.84, p = 0.01) and non-liver-related death (HR 0.26, 95% CI 0.08–0.82, p = 0.02), and was not associated with liver-related death, decrease in hepatocellular carcinoma and need for liver transplantation. The sustained virological response was 88%. According to adjusted multivariable analysis, sustained virological response achievement was associated with a decrease in all-cause mortality (HR 0.29, 95% CI 0.15–0.54, p Conclusion Treatment with direct antiviral agents is associated with reduced risk for mortality. The sustained virological response was 88%. Thus, direct antiviral agents treatment should be considered for any patient with HCV-related decompensated cirrhosis. Trial registration: ClinicalTrials.gov registry number: NCT01953458.
- Published
- 2022
6. HIGH RATES OF VIROLOGICAL RESPONSE AND MAJOR CLINICAL IMPROVEMENT DURING SOFOSBUVIR AND DACLATASVIR-BASED REGIMENS FOR THE TREATMENT OF FIBROSING CHOLESTATIC HCV-RECURRENCE AFTER LIVER TRANSPLANTATION: THE ANRS CO23 CUPILT STUDY: 60
- Author
-
Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou-Leurent, L., Radenne, S., Botta, D., Durand, F., Silvain, C., Lebray, P., Houssel-Debry, P., Kamar, N., D’alteroche, L., Calmus, Y., Bertucci, I., Diallo, A., Pageaux, G. P., and Duclos-Vallée, J. C.
- Published
- 2015
7. COL 4-01 - Parcours des patients hépatite C chronique : cohorte régionale 1993-2013
- Author
-
Hermetet, C., Dubois, F., Bacq, Y., d’Alteroche, L., Royer, B., Gaudy-Graffin, C., Roingeard, P., Desenclos, J., and Grammatico-Guillon, L.
- Published
- 2016
- Full Text
- View/download PDF
8. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation
- Author
-
Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, Hannover Medical School [Hannover] (MHH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), CHU Bordeaux [Bordeaux], Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Universitaire de Nice (CHU Nice), University Hospitals Birmingham [Birmingham, Royaume-Uni], University Medical Center Groningen [Groningen] (UMCG), Réseau CENTAURE, Hôpital Foch [Suresnes], Royal Infirmary of Edinburgh, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Paul Brousse, Centre hospitalier universitaire de Nantes (CHU Nantes), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Hôpital Claude Huriez [Lille], CHU Lille, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), CHU Strasbourg, Département de Néphrologie et Transplantation d'organes [Toulouse], Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gastroenterology & Hepatology, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université de Montpellier (UM)-CHU Saint-Eloi, Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours, Département de Néphrologie et Transplantation d'organes, Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service de néphrologie et immunologie clinique, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10
- Subjects
0301 basic medicine ,MESH: Antiviral Agents / therapeutic use ,Sofosbuvir ,viruses ,medicine.disease_cause ,Gastroenterology ,THERAPY ,Organ transplantation ,Hepatitis E virus / genetics ,Hepatitis E / drug therapy ,Humans ,chemistry.chemical_compound ,0302 clinical medicine ,Hepatitis E virus ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine ,MUTATION ,MESH: Hepatitis E* / drug therapy ,POLYMERASE ,organ transplantation ,virus diseases ,MESH: Ribavirin / therapeutic use ,Anemia ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,Hepatitis E ,anemia ,3. Good health ,PREDICTS ,Sustained virological response ,Infectious Diseases ,MESH: RNA, Viral ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,RNA, Viral ,030211 gastroenterology & hepatology ,sustained virological response ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,ribavirin ,MESH: Organ Transplantation / adverse effects ,RNA, Viral Retrospective Studies ,Ribavirin / therapeutic use ,Alpha interferon ,MESH: Organ Transplantation* / adverse effects ,hepatitis E virus ,Antiviral Agents ,Virus ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,Ribavirin ,Retrospective Studies ,MESH: Hepatitis E virus* / genetics ,MESH: Humans ,business.industry ,Retrospective cohort study ,MESH: Retrospective Studies ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,IN-VITRO ,medicine.disease ,digestive system diseases ,030104 developmental biology ,chemistry ,SOFOSBUVIR ,HEV ,REPLICATION ,INTERFERON-ALPHA ,business - Abstract
Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.
- Published
- 2020
9. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis
- Author
-
REGINA, S., HERAULT, O., DʼALTEROCHE, L., BINET, C., and GRUEL, Y.
- Published
- 2007
10. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study
- Author
-
Dumortier, Jerome, Leroy, V., Duvoux, C., Lédinghen, V., Francoz, C., Houssel-Debry, P., Radenne, S., d'Alteroche, L., Fougerou-Leurent, C., Canva, V., Martino, V., Conti, F., Kamar, Nassim, Moreno, C., Lebray, P., Tran, A., Besch, C., Diallo, A., Rohel, A., Rossignol, E., Abergel, A., Botta-Fridlund, D., Coilly, A., Samuel, D., Duclos-Vallée, J.-C., Pageaux, G.-P., Département d'hépatologie, Hospices Civils de Lyon (HCL), Epidémiologie pronostique des cancers et affections graves, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services de Maladies de l'Appareil Digestif, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille, Service d'Hépatologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Service de Transplantation, Centre Hospitalier Universitaire de Strasbourg, Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), Unité de la recherche fondamentale et clinique sur l' hépatite virale, France Recherche Nord & Sud Asdi-VIH Hépatites, Agence Nationale de Recherche sur le Sida, Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Image Science for Interventional Techniques (ISIT), Université d'Auvergne - Clermont-Ferrand I (UdA)-Clermont Université-Centre National de la Recherche Scientifique (CNRS), Service d'hépato-gastroentérologie, Hôpital de la Conception, AP-HM, Marseille, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Paul Brousse, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), National Agency for Research on Acquired Immune Deficiency Syndrome and Viral Hepatitis, Agence Nationale de Recherche sur le Sida, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Université de Montpellier (UM)-CHU Saint-Eloi, Jonchère, Laurent, and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV] Life Sciences [q-bio] ,hepatitis C virus ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,treatment ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,[SDV]Life Sciences [q-bio] ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,severe fibrosis (METAVIR F3/F4) ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,sofosbuvir-based ,transplantation - Abstract
International audience; Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrhosis and, therefore, graft failure and retransplantation or death. The aim of the present study was to assess efficacy and tolerance of sofosbuvir (SOF)–based regimens for the treatment of HCV recurrence in patients with severe fibrosis after LT. The Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation (CULPIT) study is a prospective multicenter cohort including patients with HCV recurrence following LT treated with second generation direct antivirals. The present study focused on patients included between October 2013 and November 2014 and diagnosed with HCV recurrence and liver graft extensive fibrosis (METAVIR F3/F4). A SOF-based regimen was administered to 125 patients fulfilling inclusion criteria. The median delay from LT was 95.9 ± 69.6 months. The characteristics of patients were as follows: mean age, 59.4 ± 9.0 years; 78.4% male; infected by HCV genotype 1: 78.2%, mean HCV RNA: 6.1 ± 1.0 log10 IU/mL. Eighty patients had failed previous post-LT antiviral therapy (64.0%) including triple therapy with first generation protease inhibitors in 19 (15.2%) patients. The main combination regimen was SOF/daclatasvir (73.6%). Ribavirin was used in 60 patients. Sustained virological response 12 weeks after treatment was 92.8% (on an intention-to-treat basis); 7 patients with virological failure were observed. Serious adverse events occurred in 25.6% of the patients during antiviral treatment. During antiviral treatment and follow-up, 3 patients were retransplanted and 4 patients died. In conclusion, SOF-based antiviral treatment shows very promising results in patients with HCV recurrence and severe fibrosis after LT. Liver Transplantation 22 1367–1378 2016 AASLD. © 2016 by the American Association for the Study of Liver Diseases
- Published
- 2016
11. Severity of hepatic fibrosis after Fontan operation is associated with early postoperative inferior vena cava pressure and time from surgery
- Author
-
Lefort, B., primary, Jaillais, A., additional, Aupy, B., additional, Dion, F., additional, Soulé, N., additional, El Arid, J.M., additional, Neville, P., additional, D’alteroche, L., additional, and Chantepie, A., additional
- Published
- 2018
- Full Text
- View/download PDF
12. A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis
- Author
-
Moreau, R., primary, Elkrief, L., additional, Bureau, C., additional, Pérarnau, J.-M., additional, Thévenot, T., additional, Saliba, F., additional, Louvet, A., additional, Nahon, P., additional, Oberti, F., additional, Anty, R., additional, Hillaire, S., additional, Pasquet, B., additional, Ozenne, V., additional, Rudler, M., additional, Ollivier-Hourmand, I., additional, Robic, M.-A., additional, D’Alteroche, L., additional, Di Martino, V., additional, Rautou, P.-E., additional, Gault, N., additional, and Lebrec, D., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Transjugular intrahepatic portosystemic shunt before planned abdominal surgery in cirrhotic patients
- Author
-
Tabchouri, N., primary, Barbier, L., additional, Menahem, B., additional, Perarneau, J.-M., additional, Muscari, F., additional, Dumortier, J., additional, D’Alteroche, L., additional, Lubrano, J., additional, Alves, A., additional, Bureau, C., additional, and Salamé, E., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study
- Author
-
Houssel-Debry, P., primary, Duvoux, C., additional, Coilly, A., additional, Fougerou-Leurent, C., additional, Jezequel, C., additional, De Ledinghen, V., additional, Radenne, S., additional, Kamar, N., additional, Leroy, V., additional, Di Martino, V., additional, D’Alteroche, L., additional, Canva, V., additional, Conti, F., additional, Dumortier, J., additional, Montialoux, H., additional, Lebray, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Moreno, C., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Durand, F., additional, Abergel, A., additional, Habersetzer, F., additional, Debette-Gratien, M., additional, Rohel, A., additional, Diallo, A., additional, Rossignol, E., additional, Veislinger, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
15. Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt
- Author
-
Anty, R., primary, Coilly, A., additional, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Botta-Fridlund, D., additional, Leroy, V., additional, Durand, F., additional, Tran, A., additional, Montialoux, H., additional, Habersetzer, F., additional, Favre, G., additional, Rossignol, E., additional, Rohel, A., additional, Renault, A., additional, Dharancy, S., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
16. Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study
- Author
-
Dharancy, S., primary, Coilly, A., additional, Fougerou-Leurent, C., additional, Duvoux, C., additional, Kamar, N., additional, Leroy, V., additional, Tran, A., additional, Houssel-Debry, P., additional, Canva, V., additional, Moreno, C., additional, Conti, F., additional, Dumortier, J., additional, Di Martino, V., additional, Radenne, S., additional, De Ledinghen, V., additional, D’Alteroche, L., additional, Silvain, C., additional, Besch, C., additional, Perré, P., additional, Botta-Fridlund, D., additional, Francoz, C., additional, Habersetzer, F., additional, Montialoux, H., additional, Abergel, A., additional, Debette-Gratien, M., additional, Rohel, A., additional, Vallée, J.C.D., additional, and Pageaux, G.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
17. Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.
- Author
-
Anty, R., Favre, G., Coilly, A., Rossignol, E., Houssel‐Debry, P., Duvoux, C., De Ledinghen, V., Di Martino, V., Leroy, V., Radenne, S., Kamar, N., Canva, V., D'Alteroche, L., Durand, F., Dumortier, J., Lebray, P., Besch, C., Tran, A., Canivet, C. M., and Botta‐Fridlund, D.
- Subjects
SOFOSBUVIR ,LIVER transplantation ,HEPATITIS C virus ,GLOMERULAR filtration rate ,NEPHROTOXICOLOGY ,MYCOPHENOLIC acid - Abstract
Summary: Background: In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir‐based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim: To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods: In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease–Epidemiology Collaboration (CKD‐EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre‐treatment, on‐treatment and post‐treatment periods were 9 months, 3‐9 months and 4.5 months. Interactions between eGFR slopes and the pre‐treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On‐treatment eGFR slopes were separated in tertiles. Pre‐ and post‐treatment eGFR slopes were compared globally and according to tertiles. Results: The post‐treatment eGFR slope was significantly better than pre‐treatment eGFR slope (+0.18 (IQR −0.76 to +1.32) vs −0.11 (IQR −1.01 to +0.73) mL/min/1.73 m
2 /month, P = 0.03) independently of the pre‐treatment eGFR (P = 0.99), ribavirin administration (P = 0.26), mycophenolate mofetil administration (P = 0.51) and stage of fibrosis (F3 and F4 vs lower stages, P = 0.18; F4 vs lower stages, P = 0.08; F4 Child‐Pugh B and C vs lower stages, P = 0.38). Tertiles of on‐treatment eGFR slopes were −1.71 (IQR −2.54 to −1.48), −0.78 (IQR −1.03 to −0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m2 /month. Pre‐ and post‐treatment eGFR slopes were not significantly different according to tertiles (respectively, P = 0.34, 0.08, 0.73). Conclusion: The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir‐based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program
- Author
-
Hezode, C., primary, De Ledinghen, V., additional, Fontaine, H., additional, Zoulim, F., additional, Lebray, P., additional, Boyer, N., additional, Larrey, D., additional, Silvain, C., additional, Botta-Fridlund, D., additional, Leroy, V., additional, Bourliere, M., additional, D’Alteroche, L., additional, Hubert-Fouchard, I., additional, Guyader, D., additional, Rosa, I., additional, Nguyen-Khac, E., additional, Di Martino, V., additional, Carrat, F., additional, Fedchuk, L., additional, Akremi, R., additional, Bennai, Y., additional, and Bronowicki, J.-P., additional
- Published
- 2015
- Full Text
- View/download PDF
19. P0210 : Combined partial splenic embolization (PSE) allows reducing transjugular intrahepatic portosystemic shunt (TIPS) diameter in hypersplenic cirrhotic patients: A pilot study
- Author
-
Regnault, D., primary, Geffray, A., additional, Nicolas, C., additional, D’Alteroche, L., additional, Pucheux, J., additional, Sainz Barriga, M., additional, Bucur, P., additional, Salame, E., additional, and Perarnau, J.-M., additional
- Published
- 2015
- Full Text
- View/download PDF
20. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
- Author
-
Coilly, A., primary, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Leroy, V., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Rohel, A., additional, Renault, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2015
- Full Text
- View/download PDF
21. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study
- Author
-
Dumortier, J., primary, Botta-Fridlund, D., additional, Coilly, A., additional, Leroy, V., additional, Fougerou-Leurent, C., additional, Danjou, H., additional, Radenne, S., additional, Durand, F., additional, Kamar, N., additional, di Martino, V., additional, de Ledinghen, V., additional, Houssel-Debry, P., additional, d’Alteroche, L, additional, Duvoux, C., additional, Conti, F., additional, Canva, V., additional, Diallo, A., additional, Rohel, A., additional, Duclos-Vallée, J.-C., additional, and Pageaux, G.-P., additional
- Published
- 2015
- Full Text
- View/download PDF
22. P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant)
- Author
-
Fontaine, H., primary, Maynard-Muet, M., additional, Bouix, C., additional, Botta-Fridlund, D., additional, D’Alteroche, L., additional, Conti, F., additional, Pageaux, G.-P., additional, Leroy, V., additional, Métivier, S., additional, Anty, R., additional, Durand, F., additional, Canva, V., additional, Lebray, P., additional, Alric, L., additional, Duvoux, C., additional, Petrov-Sanchez, V., additional, Beaulieux, F., additional, Willems, C., additional, Paul, C., additional, Pradat, P., additional, Duclos-Vallée, J.-C., additional, and Samuel, D., additional
- Published
- 2015
- Full Text
- View/download PDF
23. Efficacité et tolérance de l'association Gemcitabine-Oxaliplatine dans le traitement palliatif du carcinome hépatocellulaire avancé : étude multicentrique rétrospective
- Author
-
Chrysostome, B., Lagasse, Jean, Moulin, V., Viguier, J., Assor, P., d'Alteroche, L., Bourlier, P., Dorval, E., Lecomte, Thierry, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), and Dequeant, Evelyne
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
National audience
- Published
- 2008
24. P693 NEUROLOGIC DISORDERS DURING HEV INFECTION IN NONIMMUNOCOMPROMISED PATIENTS
- Author
-
Perrin, H. Blasco, primary, Cintas, P., additional, Abravanel, F., additional, Gérolami, R., additional, Couzigou, P., additional, d'Alteroche, L., additional, Prudhomme, L., additional, Buscail, L., additional, Bureau, C., additional, Vinel, J.P., additional, Izopet, J., additional, and Peron, J.M., additional
- Published
- 2014
- Full Text
- View/download PDF
25. P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIAL
- Author
-
Guyader, D., primary, Bellissant, E., additional, Asselah, T., additional, Bronowicki, J.P., additional, Abergel, A., additional, Lasser, L., additional, Tran, A., additional, Bourlière, M., additional, Samuel, D., additional, Wartelle, C., additional, Beaugrand, M., additional, Trépo, C., additional, Riachi, G., additional, Attali, P., additional, D'alteroche, L., additional, Gournay, J., additional, Vinel, J.P., additional, Schnee, M., additional, Henrion, J., additional, Doffoel, M., additional, Hillon, P., additional, Adler, M., additional, Turlin, B., additional, Renault, A., additional, Bedossa, P., additional, Calès, P., additional, and Delwaide, J., additional
- Published
- 2014
- Full Text
- View/download PDF
26. FRI-481 - Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt
- Author
-
Anty, R., Coilly, A., Fougerou, C., De Ledinghen, V., Houssel-Debry, P., Duvoux, C., Di Martino, V., Radenne, S., Kamar, N., D’Alteroche, L., Canva, V., Lebray, P., Moreno, C., Dumortier, J., Silvain, C., Besch, C., Botta-Fridlund, D., Leroy, V., Durand, F., Tran, A., Montialoux, H., Habersetzer, F., Favre, G., Rossignol, E., Rohel, A., Renault, A., Dharancy, S., Danjou, H., Duclos-Vallee, J.-C., and Pageaux, G.-P.
- Published
- 2016
- Full Text
- View/download PDF
27. FRI-483 - Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study
- Author
-
Dharancy, S., Coilly, A., Fougerou-Leurent, C., Duvoux, C., Kamar, N., Leroy, V., Tran, A., Houssel-Debry, P., Canva, V., Moreno, C., Conti, F., Dumortier, J., Di Martino, V., Radenne, S., De Ledinghen, V., D’Alteroche, L., Silvain, C., Besch, C., Perré, P., Botta-Fridlund, D., Francoz, C., Habersetzer, F., Montialoux, H., Abergel, A., Debette-Gratien, M., Rohel, A., Vallée, J.C.D., and Pageaux, G.-P.
- Published
- 2016
- Full Text
- View/download PDF
28. 581 THE PRESENCE OF A RIGHT ATRIUM–HEPATIC VEIN PRESSURE GRADIENT WORSENS THE PROGNOSIS OF CIRRHOTIC PATIENTS WITH PORTAL HYPERTENSION
- Author
-
Halle, B., primary, d'Alteroche, L., additional, Ayoub, J., additional, Salame, E., additional, and Perarnau, J.M., additional
- Published
- 2013
- Full Text
- View/download PDF
29. Imputabilité avérée de la vancomycine dans une thrombopénie profonde : à propos d’un cas clinique
- Author
-
Blandin, M., primary, Fournier, C., additional, Bacq, Y., additional, Perarnau, J., additional, D’Alteroche, L., additional, and Grassin, J., additional
- Published
- 2012
- Full Text
- View/download PDF
30. 1047 COMPARISON OF LIVER FIBROSIS BLOOD TESTS DEVELOPED FOR HCV WITH NEW SPECIFIC TESTS IN HIV/HCV CO-INFECTION
- Author
-
Calès, P., primary, Halfon, P., additional, Batisse, D., additional, Carrat, F., additional, Perré, P., additional, Penaranda, G., additional, Guyader, D., additional, D'alteroche, L., additional, Fouchard-Hubert, I., additional, Michelet, C., additional, Veillon, P., additional, Lambert, J., additional, Weiss, L., additional, Salmon, D., additional, and Cacoub, P., additional
- Published
- 2010
- Full Text
- View/download PDF
31. 101 COMPARATIVE STUDY OF HEMOSTASIS IN PERIPHERAL AND PORTAL BLOOD IN PATIENTS WITH CIRRHOSIS
- Author
-
Labat-Debelleix, V., primary, Delahousse, B., additional, d'Alteroche, L., additional, Bacq, Y., additional, Gruel, Y., additional, and Pérarnau, J.-M., additional
- Published
- 2009
- Full Text
- View/download PDF
32. P.126 Evaluation par échographie de contraste de l’effet anti-angiogénique du sorafenib dans le carcinome hépato-cellulaire
- Author
-
Goujon, G., primary, Edjlali, M., additional, Bourlier, P., additional, d’Alteroche, L., additional, Barbieux, J.P., additional, Assor, P., additional, Aubourg, A., additional, Dorval, E., additional, Tranquart, F., additional, and Lecomte, T., additional
- Published
- 2009
- Full Text
- View/download PDF
33. CO.101 Etude de l’hémostase dans le sang veineux périphérique et le sang portal chez les malades atteints de cirrhose
- Author
-
Labat-Debelleix, V., primary, Delahousse, B., additional, d’Alteroche, L., additional, Bacq, Y., additional, Gruel, Y., additional, and Perarnau, J.M., additional
- Published
- 2009
- Full Text
- View/download PDF
34. P.370 Intérêt de l’échographie de contraste pour le diagnostic de fibrose hépatique : comparaison avec l’histologie
- Author
-
Prévost, C., primary, Tournoux Facon, C., additional, Chagneau, C., additional, Staub, F., additional, Oberti, F., additional, Aube, C., additional, Bernard, P.H., additional, Trillaud, H., additional, de Ledinghen, V., additional, Drouillard, J., additional, d’Alteroche, L., additional, Tranquart, F., additional, Roumy, J., additional, Levillain, P., additional, Ingrand, P., additional, Morichaud-Beauchant, M., additional, and Tasu, J.P., additional
- Published
- 2009
- Full Text
- View/download PDF
35. Interet et apport de l’echo-doppler dans le suivi des tips (transjugular intrahepatic portosystemic shunt)
- Author
-
Ayoub, J., primary, Perarnau, J.M., additional, and D’Alteroche, L., additional
- Published
- 2008
- Full Text
- View/download PDF
36. Adénocarcinome pancréatique compliquant une dystrophie kystique sur pancréas aberrant de la région ampullaire
- Author
-
Labat-Debelleix, V., primary, d’Alteroche, L., additional, Abidine Benchellal, Z., additional, Duboeuf, T., additional, Guyétant, S., additional, and Henry Metman, É., additional
- Published
- 2008
- Full Text
- View/download PDF
37. Grossesse et hypertension portale
- Author
-
d’Alteroche, L., primary, Perarnau, J.-M., additional, Perrotin, F., additional, and Bacq, Y., additional
- Published
- 2008
- Full Text
- View/download PDF
38. Évolution à long terme d’une achalasie du sphincter inférieur de l’œsophage et d’une pseudo-obstruction intestinale paranéoplasiques révélatrices d’un carcinome pulmonaire à petites cellules
- Author
-
Ceze, N., primary, D’Alteroche, L., additional, Picon, L., additional, Magro, P., additional, Monégier du Sorbier, C., additional, and Metman, É.-H., additional
- Published
- 2008
- Full Text
- View/download PDF
39. CA 42-Faisabilité du TIPS dans la cirrhose compliquée de thrombose porte
- Author
-
Baju, A., primary, Viguier, J., additional, Bumsel, F., additional, D’Alteroche, L., additional, and Perarnau, J.M., additional
- Published
- 2006
- Full Text
- View/download PDF
40. CO 5-Évolution depuis 1994 du dépistage et de la prise en charge de l’infection par le vhc: étude chez des sujets bénéficiant d’un examen périodique de santé
- Author
-
Gaudy, C., primary, Capellier, F., additional, Giraudeau, B., additional, D’Alteroche, L., additional, Guillemard, C., additional, Fouchard-Hubert, I., additional, Tichet, J., additional, Goudeau, A., additional, and Dubois, F., additional
- Published
- 2006
- Full Text
- View/download PDF
41. P.227 Natural history of hepatitis C in twenty patients detected at the early stage of infection
- Author
-
Gaudy, C., primary, Aymond, S., additional, D'Alteroche, L., additional, Bacq, Y., additional, Barin, F., additional, Goudeau, A., additional, and Dubois, F., additional
- Published
- 2006
- Full Text
- View/download PDF
42. O.145 Changes in medical resource utilisation by subjects who are tested HCV seropositive during routine medical check-up (1994–2003)
- Author
-
Gaudy, C., primary, Capellier, F., additional, Giraudeau, B., additional, D'Alteroche, L., additional, Guillemard, C., additional, Fouchard-Hubert, I., additional, Tichet, J., additional, Goudeau, A., additional, and Dubois, F., additional
- Published
- 2006
- Full Text
- View/download PDF
43. CO11 - Effets indésirables ophtalmologiques au cours du traitement des hépatites virales par interféron alpha : étude prospective de 156 malades
- Author
-
D’Alteroche, L., primary, Majzoub, S., additional, Lecuyer, A.I., additional, Delplace, M.P., additional, and Bacq, Y., additional
- Published
- 2004
- Full Text
- View/download PDF
44. Épanchement péricardique révélateur d’une insuffisance cardiaque à débit élevé par carence en thiamine chez un adulte jeune
- Author
-
Hurreesing, C, primary, Babuty, D, additional, Fauchier, L, additional, d’Alteroche, L, additional, Montout, M, additional, Poret, P, additional, and Cosnay, P, additional
- Published
- 2000
- Full Text
- View/download PDF
45. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis.
- Author
-
Perarnau J, Baju A, D'Alteroche L, Viguier J, and Ayoub J
- Published
- 2010
- Full Text
- View/download PDF
46. Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.
- Author
-
Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, and Albillos A
- Abstract
Background & Aims: Fontan-type surgery is used as a palliation for congenital heart disease with univentricular physiology but may, in the long term, lead to advanced chronic liver disease. This study assessed the accuracy of conventional non-invasive models in assessing liver fibrosis and introduces a new risk score employing non-invasive tools., Methods: A prospective, cross-sectional, observational study was conducted across five European centers and encompassing all consecutive adult patients with Fontan circulation, liver biopsy and non-invasive tests (elastography, APRI, FIB-4, Fibrosis score, Doha, GUCI, and AAR). The primary outcome was the identification of severe liver fibrosis on biopsy. Multivariable logistic regression identified non-invasive predictors of severe fibrosis, leading to the development and internal validation of a new scoring model named the FonLiver risk score., Results: In total, 217 patients (mean [standard deviation] age, 27.9 [8.9] years; 50.7% males) were included. Severe liver fibrosis was present in 47.9% (95% CI 41.2%-54.5%) and correlated with a lower functional class, protein-losing enteropathy, and compromised cardiopulmonary and systemic hemodynamics. The final FonLiver risk score incorporated liver stiffness measurement using transient elastography and platelet count and demonstrated strong discrimination and calibration (area under the receiver operating curve [AUROC] of 0.81). The FonLiver risk score outperformed conventional prediction models (APRI, FIB-4, Fibrosis score, Doha, GUCI, and AAR), which all exhibited worse performance in our cohort (AUROC < 0.70 for all)., Conclusion: Severe liver fibrosis is prevalent in adults following Fontan-type palliation and can be effectively estimated using with the novel FonLiver risk score. This scoring system can be easily incorporated into the routine assessment of patients with Fontan circulation., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest that pertain to this work., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
47. High diagnostic value of transient elastography for advanced fibrosis and cirrhosis in patients with chronic hepatitis delta.
- Author
-
Roulot D, Brichler S, Layese R, d'ALTEROCHE L, Ganne-Carrie N, Stern C, Saviano A, Leroy V, Roudot-Thoraval F, and de Ledinghen V
- Abstract
Background & Aims: Liver biopsy remains the gold standard for fibrosis staging in patients with chronic hepatitis delta (CHD). Here we comparatively evaluated the performance of transient elastography (TE) and biomarkers for the diagnosis of liver fibrosis in patients with CHD., Methods: 230 HDV-infected RNA-positive patients from various centers who underwent liver biopsy and liver stiffness measurements (LSM) using Fibroscan®, within a period of 6 months maximum, were investigated retrospectively. AUROC and Youden index were used to establish cut-off values of LSM. TE was compared with other noninvasive tests (NITs): APRI, Fibrosis-4 and Delta-4 fibrosis scores., Results: Histologic fibrosis stage distribution was: 20.4% for F0-F1; 27.0% for F2; 18.7% for F3 and 33.9% for F4. TE demonstrated good diagnostic performance for detecting cirrhosis and advanced fibrosis with AUROC of 0.88 and 0.86, values, which were significantly higher than those obtained with the other NITs (P = .004 and P < .001). With a cutoff value >12 kPa for cirrhosis, sensitivity was 70.5%, specificity 86.2%, positive predictive value (PPV) 72.4% negative predictive value (NPV) 85.1% and accuracy 80.9%. Using 10.4 kPa as cut-off value for F3, sensitivity was 70.2%, specificity 83.5%, PPV 82.5%, NPV 71.7% and accuracy 76.5%. In 89% of patients with LSM ≤ 6.2 kPa, liver biopsy disclosed only absent or minimal fibrosis., Conclusion: TE demonstrated good diagnostic performance for advanced fibrosis and cirrhosis in CHD patients. Advanced fibrosis is highly probable for LSM values ≥10 kPa. LSM values < 6 kPa almost totally exclude significant fibrosis. Between 6 and 10 kPa, liver biopsy should be discussed., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
48. The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience.
- Author
-
Leideck P, Nkontchou G, Elkrief L, Erard D, d'Alteroche L, Radenne S, Billioud C, Meszaros M, Regnault D, Pageaux GP, Hilleret MN, Tripon S, Guillaud O, Ollivier-Hourmand I, Ganne-Carrié N, and Dumortier J
- Subjects
- Humans, Retrospective Studies, Middle Aged, Aged, Adult, Female, Male, France epidemiology, Aged, 80 and over, Adolescent, Young Adult, Thrombocytopenia etiology, Cohort Studies, Time Factors, Embolization, Therapeutic methods, Hypertension, Portal complications, Hypertension, Portal therapy, Hypersplenism therapy, Hypersplenism etiology
- Abstract
Background: Partial splenic embolization (PSE) has been proposed to treat the consequences of hypersplenism in the context of portal hypertension, especially thrombocytopenia. However, a high morbidity/mortality rate has made this technique unpopular. We conducted a multicenter retrospective nationwide French study to reevaluate efficacy and tolerance., Methods: All consecutive patients who underwent PSE for hypersplenism and portal hypertension in 7 tertiary liver centers between 1998 and 2023 were included., Results: The study population consisted of 91 procedures in 90 patients, with a median age of 55.5 years [range 18-83]. The main cause of portal hypertension was cirrhosis (84.6 %). The main indications for PSE were (1) an indication of medical treatment or radiological/surgical procedure in the context a severe thrombocytopenia (59.3 %), (2) a chronic hemorrhagic disorder associated with a severe thrombocytopenia (18.7 %), and (3) a chronic pain associated with a major splenomegaly (9.9 %). PSE was associated with a transjugular intrahepatic portosystemic shunt in 20 cases. Median follow-up after PSE was 41.9 months [0.5-270.5]. Platelet count increased from a median of 48.0 G/L [IQR 37.0; 60.0] to 100.0 G/L [75.0; 148]. Forty-eight patients (52.7 %) had complications after PSE; 25 cases were considered severe (including 7 deaths). A Child-Pugh B-C score (p < 0.02) was significantly associated with all complications, a history of portal vein thrombosis (p < 0.01), and the absence of prophylactic antibiotherapy (p < 0.05) with severe complications., Conclusion: Our results strongly confirm that PSE is very effective, for a long time, although a quarter of the patients experienced severe complications. Improved patient selection (exclusion of patients with portal vein thrombosis and decompensated cirrhosis) and systematic prophylactic antibiotherapy could reduce morbidity and early mortality in the future., Competing Interests: Declaration of competing interest The authors have no conflict of interest to disclose., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
49. Left gastric vein embolization during TIPS placement for acute variceal bleeding has no effect on bleeding recurrence: Results of a multicenter study.
- Author
-
Calame P, Rostam M, d'Alteroche L, Malakhia A, Cervoni JP, Weil D, Martino VD, Sutter O, Greget M, Risson JR, Vionnet M, Bouvier A, Mokrane FZ, Ghelfi J, Papadopoulos P, Sangel C, Rodes A, Goupil J, Delabrousse E, Douane F, and Loffroy R
- Subjects
- Male, Humans, Middle Aged, Aged, Female, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage surgery, Recurrence, Portal Vein, Esophageal and Gastric Varices complications, Esophageal and Gastric Varices surgery, Portasystemic Shunt, Transjugular Intrahepatic methods
- Abstract
Purpose: The purpose of this study was to evaluate whether concomitant left gastric vein embolization (LGVE) during transjugular intrahepatic portosystemic shunt (TIPS) for acute variceal hemorrhage could reduce the risk of bleeding recurrence., Material and Method: A national multicenter observational study was conducted in 14 centers between January 2019 and December 2020. All cirrhotic patients who underwent TIPS placement for acute variceal bleeding were included. During TIPS procedure, size of left gastric vein (LGV), performance of LGVE, material used for LGVE and portosystemic pressure gradient (PPG) before and after TIPS placement were collected. A propensity score for the occurrence of LGVE was calculated to assess effect of LGVE on rebleeding recurrence at six weeks and one year., Results: A total of 356 patients were included (mean age 57.3 ± 10.8 [standard deviation] years; 283/356 [79%] men). Median follow-up was 11.2 months [interquartile range: 1.2, 13.3]. The main indication for TIPS was pre-emptive TIPS (162/356; 46%), rebleeding despite secondary prophylaxis (105/356; 29%), and salvage TIPS (89/356; 25%). Overall, 128/356 (36%) patients underwent LGVE during TIPS procedure. At six weeks and one year, rebleeding-free survival did not differ significantly between patients who underwent LGVE and those who did not (6/128 [5%] vs. 15/228 [7%] at six weeks, and 11/128 [5%] vs. 22/228 [7%] at one year, P = 0.622 and P = 0.889 respectively). A total of 55 pairs of patients were retained after propensity score matching. In patients without LGVE, the rebleeding rate was not different from those with LGVE (3/55 [5%] vs. 4/55 [7%], P > 0.99, and 5/55 [9%] vs. 6/55[11%], P > 0.99, at six weeks and one year respectively). Multivariable analysis identified PPG after TIPS placement as the only predictor of bleeding recurrence (hazard ratio = 1.09; 95% confidence interval: 1.02-1.18; P = 0.012)., Conclusion: In this multicenter national real-life study, we did not observe any benefit of concomitant LGVE during TIPS placement for acute variceal bleeding on bleeding recurrence rate., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
- Author
-
Louvet A, Bourcier V, Archambeaud I, d'Alteroche L, Chaffaut C, Oberti F, Moreno C, Roulot D, Dao T, Moirand R, Duclos-Vallée JC, Goria O, Nguyen-Khac E, Pol S, Carbonell N, Gournay J, Elkrief L, Fouchard-Hubert I, Chevret S, and Ganne-Carrié N
- Subjects
- Male, Humans, Female, Prospective Studies, Liver Cirrhosis complications, Ethanol, Liver Cirrhosis, Alcoholic complications, Liver Neoplasms
- Abstract
Background & Aims: The harmful impact of heavy alcohol consumption and recurrence in patients with alcohol-related cirrhosis is long-established, although this is based on old studies. However, the drivers of long-term outcome still need to be clearly investigated., Method: All patients with biopsy-proven compensated alcohol-related cirrhosis included in the CIRRAL cohort (22 centers) were prospectively studied. Prognostic variables of survival and liver event-free survival were assessed using multivariable Cox models with stepwise selection. The prognostic impact of alcohol recurrence during follow-up (computed in glass-years in the same way as pack-years for tobacco) was assessed using a time-dependent covariable., Results: From 2010 to 2016, 650 patients were included. The median age at baseline was 58.4 years, 67.4% were men and the median BMI was 27.8 kg/m
2 , 63.8% had a history of liver decompensation, and 70.2% had discontinued alcohol. At 5 years, recurrence occurred in 30.9% of abstinent patients and this risk was higher in patients with a history of drug abuse and in those with shorter alcohol discontinuation times. Median survival was 97 months. Age, alcohol consumption at baseline, platelet count and Child-Pugh score >5 were associated with overall and liver event-free survival on multivariate analysis. Alcohol consumption of more than 25 glass-years during follow-up was independently associated with lower survival and with a trend toward lower liver event-free survival, with the risk increasing from 1 glass-year, though not significantly. Simon & Makuch plots confirm the benefit of no alcohol consumption (<1 glass/week) on both outcomes and the dose-dependent impact of alcohol over time., Conclusion: This prospective study in patients with compensated alcohol-related cirrhosis identifies factors predictive of alcohol recurrence during follow-up and shows that moderate alcohol consumption during follow-up negatively impacts outcomes. Patients with alcohol-related cirrhosis should be advised to completely stop drinking alcohol., Registration: CIRRAL (NCT01213927) cohort was registered at ClinicalTrials.gov and the full protocol is available at the following link: https://clinicaltrials.gov/ct2/show/NCT01213927., Impact and Implications: In patients with alcohol-related cirrhosis, data are lacking about the impact of the amount of alcohol consumed on both survival and liver-related events. The present study based on the CIRRAL cohort demonstrates that alcohol recurrence occurs in more than 30% of patients with compensated cirrhosis and that even a moderate recurrence strongly influences outcomes. Patients with compensated alcohol-related cirrhosis should be advised to completely discontinue alcohol consumption, even in small amounts, as the present study shows that no alcohol consumption can be regarded as safe when cirrhosis has developed., (Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.